BeatO raises INR 11-75 Crore in pre-Series A round of funding
Category: #health  By Pankaj Singh  Date: 2019-03-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

BeatO raises INR 11-75 Crore in pre-Series A round of funding
  • Apart from Orios Venture Partners, BeatO’s existing investors, Leo Capital & Blume Ventures also participated in the pre-Series A funding round.
  • The proceeds from the funding round would be utilized to further expand the company’s existing flagship glucometer product line and its retail & FMCG categories.

BeatO, a New Delhi-based health-technology startup, has reportedly announced the completion of a INR 11.75 crore pre-Series A funding round led by investor Orios Venture Partners (Orios VP).

Reports cite, apart from Orios VP, BeatO’s existing investors, Leo Capital & Blume Ventures also participated in the early-stage funding round. Proceeds from the funding round would be utilized to further expand the company’s existing flagship glucometer product line and would also go into its retail & FMCG categories.

According to a report by India FMCG News, the company would also be allocating a significant portion of the raised capital to its dedicated research & development R&D division, for upgradation of platform for auto-suggestions based readings of blood-sugar as well as for expediting product development.

The Managing Partner of Orios Venture Partners, Anup Jain stated that the diabetic population across the nation has reached 80 million and is further growing at a CAGR of more than 6%. BeatO facilitates the one platform where diabetes can be effectively managed & monitored by the user & caregivers in an extremely convenient manner.

The Chief Executive Officer of BeatO, Gautam Chopra stated that the growing disposable income across the Indian middle-class would increasingly lead to more discretionary spending in coming years. Chopra added, for a diabetic person, the company expects this income to be channeled into an increased consumption of different customized food & retail products as well as personalized management solutions.

According to reports, the exact amount invested by Orios Venture Partners into BeatO during the funding round has not been disclosed yet.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...